原发性肝癌是临床上最常见的恶性肿瘤之一，其中90%为肝细胞癌（HCC），其他病理类型有胆管细胞癌（ICC）和混合型肝癌等。肝癌俗称“癌中之王”。

Primary liver cancer is one of the most common malignant tumor in clinical practice,90% for hepatocellular carcinoma (HCC)(HCC),Other pathological types with bile duct carcinoma(The ICC)And hybrid liver cancer, etc.Liver cancer known as"The king of cancer".

　　肝癌主要高发区为中国、东南亚、非洲东南部和地中海沿岸。与世界其他地区的肝癌相比，亚太区，特别是我国肝癌病人生存期短、预后更差，其主要原因是东西方肝癌存在着高度异质性，在病因学、分期、恶性生物学行为（临床表现）以及诊治策略等方面，都存在有显著的差异，故有多位学者认为应将其看成是“两种疾病”。非常有必要去针对亚洲人群，特别是中国患者群专门设计大型临床研究，探索适合的诊疗方案。因此，可以说肝癌是一种具有“中国特色的肿瘤”。

Main high incidence of liver cancer in China/In southeast Asia/Southeast of Africa and the Mediterranean coast.Compared with the liver cancer in other parts of the world,Asia Pacific region,Especially liver cancer patients survival period is short in our country/The prognosis is worse,The main reason is that east and west there is a highly heterogeneity of cancer of the liver,In the aetiology/installment/Malignant biological behavior(Clinical manifestations)And make a diagnosis and give treatment strategy, etc,There are significant differences,So a number of scholars believe that should be considered"Two kinds of disease".Is very necessary to go to Asian people,Especially Chinese patients group of specially designed large clinical studies,To explore the diagnosis and treatment plan.so,Hepatocellular carcinoma is one kind has, so to speak"Chinese characteristics of tumors".

　　在我国肝癌高发，发病率和病死率都位居全球第一, 并且超过了全球的一半；肝癌高居我国肿瘤死因的第2位。每年有43多万例新发的肝癌病人。为此，国家卫生部专门成立了肝癌专家组，制定了诊断治疗规范，正在组织全国性肝癌病例登记,调整战略决策。

High incidence of liver cancer in our country,Morbidity and mortality are among the world's first, And more than half of the world;Cancer of the liver tumor second leading cause of death in our country.Every year, more than 43 new patients with liver cancer cases.To do this,National ministry of health set up a panel of liver cancer,Made the diagnosis and treatment norms,Is organizing a national registered cases of liver cancer,Adjust the strategic decision.

　　对于肝癌，更加强调多学科协作，多方法治疗。在根治性治疗方面，首选外科手术，包括肝切除手术和肝移植，而对于早期肝癌，也可采用局部消融技术；在姑息性治疗方面，常用局部消融和介入治疗。，或者说是全身性疾病基础上的局部表现，单独依靠手术和其他局部治疗不能治愈； 而且无论是根治性切除，还是肝移植都不能防止其复发。在我国，大多数肝癌（85%）患者在确诊时，已经达到巴塞罗那肝癌临床分期（BCLC分期）的中、晚期，且78%的患者伴有肝脏疾病（以乙型病毒性肝炎和肝硬化为主），不能进行手术、局部消融或是介入治疗，一年死亡率高达90%。

For liver cancer,More emphasis on the multidisciplinary collaboration,Treatments for more.In the radical treatment,The preferred surgical procedure,Including liver surgery and liver transplantation,For early liver cancer,And local ablation technique can be applied;In the palliative treatment,Commonly used local ablation and interventional therapy.,Or partial performance on the basis of systemic diseases,Rely on operations and other local treatment alone will not cure; And whether it is a radical resection,Or liver transplantation can prevent its recurrence.In our country,Most of the cancer of the liver(85%)Patients at the time of diagnosis,Has reached Barcelona clinical staging of liver cancer(BCLC staging)In the/In the late,And 78% of the patients with liver diseases(Give priority to with hepatitis b viral hepatitis and liver cirrhosis),Not for surgery/Partial melting or interventional therapy,Mortality rates as high as 90% a year.

　　作为国家卫生部肝癌专家组组长，秦叔逵教授指出，对于中晚期肝癌病人，有必要应用内科药物，包括分子靶向药物、新一代化疗药物和现代中药制剂等，已成为不可或缺的治疗手段；可以减轻症状、稳定病情，是提高生存质量、延长带瘤生存时间的重要环节，有时甚至是中晚期肝癌治疗的最后一道防线。近年来，系统治疗，特别是分子靶向治疗和系统化疗取得了长足的进步。因此, 对于中晚期肝细胞癌，内科治疗必不可少, 是防止复发、转移，提高患者的生存质量，延长其生存时间的重要方法。崔娉 整理

As a liver cancer expert group leader at the national institutes of health,Professor Qin Shukui pointed out,For locally advanced hepatocellular carcinoma patients,It is necessary to use medical drugs,Including the molecular targeted drugs/A new generation of chemotherapy medicines and modern traditional Chinese medicine preparations, etc,Has become an integral part of treatment;Can alleviate the symptoms/Stable condition,Is to improve the quality of life/An important part of the extension of survival time with tumor,Sometimes even middle-late last defense line of the treatment of liver cancer.In recent years,System treatment,Especially the molecule targeted therapy and systematic chemotherapy has achieved great progress.so, For locally advanced hepatocellular carcinoma (HCC),Medical treatment is necessary, Is to prevent the recurrence/transfer,Improve the quality of the survival of patients,Important way to prolong the survival time.Cui ping to sort out